ICYMI: Reduction of AxSpa-Associated Acute Anterior Uveitis with Certolizumab Acute anterior uveitis (AAU) is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA), affecting up to 50% of patients in some age groups. https://t.co/wn5iDXibzi https://t.co/IVtKwdYDwN

Programmed-cell-death 1 (PD-1) expression on T-cells is assoc w/ activation & exhaustion. The exhausted phenotype of PD-1+CD8+ T cells add to the pathogenesis of active idiopathic inflammatory myositis. https://t.co/TRgtYCbnf2 https://t.co/7xgBU3apmy

EULAR 2023 Recommendations on Fatigue Fatigue is highly prevalent in inflammatory rheumatic and musculoskeletal diseases (I-RMDs) patients, is often unaddressed and yet it has significant effects on patient quality of life. https://t.co/e2pP8bt9jg https://t.co/7R58j1oZKR

RheumNow Live is rapidly approaching. Are you registered? Amongst our 25 speakers, Dr. Kahlenberg will cover Biology and RX of Lupus Flares. Dr. Fava will cover Current/Future Biomarkers in SLE, all in a session on The Future of SLE Management. https://t.co/aJ8ciU3auI https://t.co/0WgD0dmLiE

IL-18 excess is assoc. w/ autoinflammatory Dz, "IL-18opathies". High IL-18 associated w/ #MAS & PSTPIP1-related diseases (eg, PAPA syndr. Pyogenic arthritis, pyoderma gangrenosum, acne)IL-18 binding protein is a biomarker of IFNγ activity. https://t.co/dy3xHdgTXX https://t.co/qBvCHvtsu7

PsA undergoing lumbar degenerative disease (LDD) surgery have 2 fold higher risk of VTE. National Inpatient study 471,283 LDD surgeries showed PsA had higher overall morbidity (9 % v 7 %), VTE (1.4 % v 0.7 %), unfavorable D/C(21% v. 17 %). https://t.co/C0eimmwEmm https://t.co/58PoJOJEeY

RA pts more likely to get autoimmune thyroid Dz (AITD), but after dx, AITD risk signif. drops (HR 0.81), suggesting RA Rx lowers AITD risk; greater drop in biologic Rx RA (HR 0.54).Swiss registry compared 13,731 new-onset RA pts to 63,201 matched controls https://t.co/n0n2EfUyqR https://t.co/yMMHvYRsyY

Cannabis Use in Rheumatic Diseases Dr. Janet Pope discusses several abstracts presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/C2vbbERoHZ https://t.co/XeiS0cJjuy

INVIGORATE-1 Study: IV Secukinumab for Treatment of Active axSpA Dr. Atul Deodhar reports on abstract 2545 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/Fhv7dhDTJA https://t.co/Zz0PwFjOD4

CDC: Chronic Fatigue Syndrome 2021-2022 The current CDC report estimates that 1.3% of adults had myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), based on the most recent population based National Health Interview Survey (NHIS 2021–2022). https://t.co/4LeQ7DJPyI https://t.co/5ITG46d25M

ICYMI: Cancer and TNF inhibitors Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. https://t.co/rNSTcT5O6L https://t.co/f5lvMTH7ik

The ARGO Project for Rheumatology Fellows Dr. Sheila Reyes (Philippines) talks with Dr. Lisa Traboco about abstract 2078, presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/RRjc38JpEQ https://t.co/q9rCxbWzNh